NCM · Biotechnology

Nektar Therapeutics (NKTR) Stock

$41.17 +0.91% NCM: NKTR Healthcare

Valuation

MetricValue
Price$41.17
Market Cap$1.18B
P/E Ratio-6.50
P/B Ratio1.60
P/S Ratio22.90
EPS (TTM)$-9.73
52-Week High$109.00
52-Week Low$33.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.99%
ROA-14.35%
ROCE-12.81%
Gross Margin-238.18%
Operating Margin-238.18%
Net Margin-287.84%
Debt/Equity0.15
Current Ratio4.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$102.0M$92.0M$90.0M$98.0M$55.0M
Operating Profit$-446.0M$-240.0M$-137.0M$-105.0M$-131.0M
Net Profit$-524.0M$-368.0M$-276.0M$-119.0M$-164.0M
EPS$-42.90$-29.51$-21.79$-8.68$-9.73
Op Margin-437.8%-261.0%-152.5%-106.9%-236.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$711.0M$398.0M$304.0M$280.0M
Total Liabilities$438.0M$344.0M$267.0M$243.0M$191.0M
Cash$25.0M$88.0M$35.0M$44.0M$15.0M
Borrowings$143.0M$131.0M$118.0M$103.0M$149.0M

Latest News

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema Stocktwits · Jul 3, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire · Jun 26, 2026 What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year Motley Fool · Jun 24, 2026 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal 24/7 Wall St. · Jun 23, 2026 Nektar Therapeutics Insider Sold Shares Worth $1,215,056, According to a Recent SEC Filing MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-413.0M$-304.0M$-193.0M$-176.0M$-209.0M
Investing Cash Flow$188.0M$360.0M$139.0M$141.0M$-1.0M
Financing Cash Flow$3.0M$1.0M$0$12.0M$0
Net Cash Flow$-174.0M$63.0M$-53.0M$9.0M$-29.0M
Free Cash Flow$-428.0M$-310.0M$-193.0M$-177.0M$-209.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.68
EV / EBITDA-10.02
FCF Yield-18.72%
Quick Ratio10.42
Interest Coverage-4.24
Return 1Y177.44%
Return 3Y772.45%
Return 5Y-73.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
CGENCompugen Ltd. $2.13 +0.47% 6.15 $201.40M 0.00%
CHRSCoherus Oncology, Inc. $1.07 +0.00% -1.10 $165.32M 0.00%
CRVSCorvus Pharmaceuticals, Inc. $10.52 +3.04% -17.03 $884.63M 0.00%
IMCRImmunocore Holdings plc $31.95 -3.42% -85.34 $1.62B 0.00%

About Nektar Therapeutics

Nektar Therapeutics is led by CEO Howard W. Robin, employs 61 people, headquartered in US, publicly traded since 1994.

Nektar Therapeutics (NKTR) stock trades at $41.17 with a market capitalization of $1.18B. The stock is valued at a price-to-earnings (P/E) ratio of -6.50, price-to-book of 1.60, price-to-sales of 22.90. Over the past 52 weeks the stock has ranged between $33.40 and $109.00, and currently trades 62.2% below its 52-week high.

On profitability, Nektar Therapeutics generates a return on equity (ROE) of -37.99%, return on capital employed of -12.81%, an operating margin of -238.18%, a net profit margin of -287.84%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides